Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAiRegenerative MedicineMolecular Targeted TherapeuticsCell TherapyGene Therapy

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1354677

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1354677

Molecular Cytogenetics

PUBLISHED:
PAGES: 657 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

What`s New?

» Special discussions on the global economic climate and market sentiment

» Coverage on global competitiveness and key competitor percentage market shares

» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass™ research platform

» Complimentary updates for one year

» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Molecular Cytogenetics Market to Reach $3.5 Billion by 2030

The global market for Molecular Cytogenetics estimated at US$1.8 Billion in the year 2022, is projected to reach a revised size of US$3.5 Billion by 2030, growing at a CAGR of 8.7% over the period 2022-2030. Consumables, one of the segments analyzed in the report, is projected to record 8.8% CAGR and reach US$2 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 7.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $794.6 Million, While China is Forecast to Grow at 10% CAGR

The Molecular Cytogenetics market in the U.S. is estimated at US$794.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$231.4 Million by the year 2030 trailing a CAGR of 10% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.2% and 7.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Abbott Molecular, Inc.
  • F. Hoffmann-La Roche AG
  • CytoSport, Inc.
  • Esperite NV
  • Eurofins Scientific SE
  • GeneDx
  • Empire Genomics LLC
  • BioDiscovery, Inc.
  • FUJIFILM Irvine Scientific
  • ADS Biotec, Inc.
  • BIOVIEW Ltd.
Show more
Product Code: MCP-6759

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of COVID-19 and a Looming Global Recession
    • COVID-19 Leaves the World in Shambles & Industries and Markets Upended: World Economic Growth Projections (Real GDP, Annual % Change) for 2019E to 2022F
    • Challenges and Opportunities for Clinical Diagnostics amid the Pandemic
    • French Research Team Develops CoronaFISH
    • Immuno RNA Fluorescence ISH for Visualization of COVID-19 Causing SARS-CoV-2
    • Molecular Cytogenetics Technologies: An Introductory Prelude
    • Future Prospects Remain Favorable for Cytogenetics Technologies
    • Uptrend in Life Sciences R&D and Healthcare Spending Creates Fertile Environment
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Northbound Trajectory in Med Tech Sector to Generate Parallel Opportunities
    • Developed Regions: Key Revenue Contributors
    • Developed Regions Account for Lion's Share of World Molecular Cytogenetics Technologies Market: Percentage Breakdown of Revenues for Developed and Developing Regions (2020E & 2027P)
    • Fast Paced Growth Projected in Developing Regions
    • Global Market for Molecular Cytogenetics Technologies - Geographic Regions Ranked by % CAGR (Revenues) for 2020-2027: China, Asia-Pacific, Latin America, USA, Middle East, Africa, Canada, Europe, and Japan
    • Competitive Scenario
    • Recent Market Activity
    • Molecular Cytogenetics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Critical Importance of Molecular Biology in Laboratory Processes: Cornerstone for Present & Future Growth
    • Advanced Molecular Biology Techniques Broaden the Scope of Cytogenetics Technologies
    • Comparative Genome Hybridization (CGH): Largest & Fastest Growing Market Segment
    • Rising Adoption of Array Based CGH to Spur Overall Demand
    • Array-based Technologies Continue to Cannibalize Sales from FISH Technology: Percentage (%) Share of Array-Based Solutions in World Cytogenetics Technologies Market (2018 & 2022)
    • aCGH Simplifies Diagnosis of Chromosomal Anomalies
    • Clinical Pathological Testing: A Growing Vertical for aCGH
    • Impact of Rising Emphasis on R&D on Microarray Technology
    • Leveraging Established Use Case, FISH Technology Continues to Find Favor
    • Next Generation Sequencing Seeks Role in Cytogenetics Processes
    • Molecular Cytogenetics Greatly Benefit Cancer Prognosis
    • Breakdown of Total Number of Cancer Cases by Region: 2020
    • Breakdown of Total Number of Cancer Cases by Type: 2020
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Cancer Care Made Easier with Highly-Multiplexed FISH
    • Diverse Applications of FISH Technology in Oncology
    • Growing Demand for Targeted Therapies in Cancer Treatment Presents Lucrative Opportunities
    • Increasing Significance of Cytogenetic Analysis in Genetic Disease Diagnosis
    • Uptrend in Genetic Disease Testing Augments Prospects
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
    • Top Ten Genetic Diseases Worldwide
    • Proven Efficacy in Nucleic Acid Diagnostics Favors Market Growth
    • Expanding Role of Molecular Cytogenetics in Personalized Medicine
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • World Personalized Medicine Market by Region/Country (2021): Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World
    • Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
    • Companion Diagnostics Lead the Way to Personalized Medicine
    • Digitalization, Automation and AI Trends Set to Shape Future Growth
    • Lab Automation Speeds Up
    • World Laboratory Automation Market in US$ Billion for Years 2018, 2020, 2022, 2024 & 2026
    • Laboratory 4.0 Set to Transform Molecular Cytogenetics Landscape
    • Laboratory Information Systems Gain Traction
    • Artificial Intelligence : The Future of LIS
    • Biotech Research Spending Patterns Steer Momentum
    • Technology Advancements & Improvements Bolster Growth
    • Ageing Demographics to Drive Demand
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
    • Technology Overview
    • A Preface to Cytogenetics
    • Basic Terms and Definitions in Molecular Biology
    • An Overview of Select Chromosomal Anomalies
    • Insight into Molecular Cytogenetics Techniques
    • Fluorescence in situ Hybridization (FISH)
    • Comparative Genomic Hybridization (CGH)
    • Advent of Microarray Technology
    • Microarrays in Comparative Genomic Hybridization
    • Principle Underlying aCGH
    • Low Resolution and High Resolution aCGH
    • A Review of Molecular Biology Techniques in Cytogenetics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Molecular Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Molecular Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for CGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for CGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for CGH by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for FISH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for FISH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for FISH by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Karyotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Karyotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Karyotyping by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Techniques by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 33: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 36: World 16-Year Perspective for Personalized Medicine by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 39: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Clinical & Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Clinical & Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 42: World 16-Year Perspective for Clinical & Research Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 45: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 46: World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 47: World Historic Review for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 48: World 16-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 49: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 50: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 51: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 52: World Molecular Cytogenetics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • The United States: Prime Market for Cytogenetics Technologies
    • CGH Technologies Witness Higher Adoption
    • Established Role Sustains Momentum in FISH Technology
    • Ageing Population and Growing Incidence of Cancer & Lifestyle Diseases - Opportunity Indicators
    • US Elderly Population: Expected Growth Rates Over the Years 2005-2025
    • Leading Sites of New Cancer Cases in Males: 2020
    • Leading Sites of New Cancer Cases in Females: 2020
    • Emphasis on Personalized Medicine & Companion Diagnostics Widens Scope
    • US Personalized Medicine Market: Breakdown of Revenues (in US$ Billion) for 2014, 2018 and 2022
    • US Companion Diagnostics (CDx) Market: Breakdown of Revenues (in US$ Million) for 2014, 2018 and 2022
    • Growing Focus on Genetic Testing Widens the Business Case
    • Emphasis on Early Diagnosis & Need to Reduce Healthcare Costs Augment Demand
    • TABLE 53: USA Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • CANADA
    • An Overview
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • Number of New Cancer Cases in Canada: 2019
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: Canada 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • JAPAN
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • Japan Offers Robust Opportunities
    • Japanese Elderly (65+ Years) Population: 2000-2020
    • Breakdown of Population by Age Group in Japan: 2010, 2020, and 2025
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Japan 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • CHINA
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • Market Overview
    • TABLE 89: China Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: China 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: China 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: China 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: China 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • EUROPE
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • A Mature yet Growing Market
    • Number of New Cancer Cases in Europe: 2012, 2018, and 2025
    • Distribution of New Cancer Cases by Type in Europe: 2018
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Molecular Cytogenetics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Molecular Cytogenetics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: Europe 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • FRANCE
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: France 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: France 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: France 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: France 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • GERMANY
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: Germany 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Italy 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • Market Overview
    • TABLE 152: UK Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: UK 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: UK 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: UK 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: UK 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: Spain 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: Russia 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Molecular Cytogenetics by Component - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for Molecular Cytogenetics by Component - Percentage Breakdown of Value Revenues for Consumables, Instruments and Software & Services for the Years 2014, 2023 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Molecular Cytogenetics by Technique - CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for Molecular Cytogenetics by Technique - Percentage Breakdown of Value Revenues for CGH, FISH, Immunohistochemistry, Karyotyping and Other Techniques for the Years 2014, 2023 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Molecular Cytogenetics by Application - Genetic Disorders, Cancer, Personalized Medicine and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for Molecular Cytogenetics by Application - Percentage Breakdown of Value Revenues for Genetic Disorders, Cancer, Personalized Medicine and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Molecular Cytogenetics by End-Use - Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: Rest of Europe 16-Year Perspective for Molecular Cytogenetics by End-Use - Percentage Breakdown of Value Revenues for Clinical & Research Laboratories, Pharma & Biotech Companies, Academic Research Institutes and Other End-Uses for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Molecular Cytogenetics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • Market Overview
    • Factors Driving Demand for Laboratory Technologies in Asia-Pacific
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!